A double-blind study of bupropion and placebo in depression

Abstract

Bupropion HCl, a new nontricyclic antidepressant, produced marked improvement in 49 hospitalized patients with primary depression at doses of 300-600 mg/day. Bupropion resulted in statistically significant differences from placebo as early as day 5; by the end of the 4-wk study, 79% (N = 27) of the bupropion patients and 13% (N = 2) of the placebo patients showed a great deal of improvement. Bupropion and placebo had similar side effect profiles. Tremor and sweating were reported more often with bupropion and headache, nausea and tiredness with placebo.